Key Highlights:
- BioSpring and Luxna extend their existing agreement, enabling BioSpring to manufacture custom next-generation oligonucleotides..
June 15, 2026
BioSpring and Luxna Biotech Extend Strategic XNA Partnership to Include GuNA™ Amidites
December 2, 2025
Luxna deepens collaboration with BioSpring to Advance Therapeutic Oligonucleotide Development
Osaka, Japan, December 2, 2025. Luxna Biotech Co., Ltd. (President CEO: Hideaki Sato; Headquarters: Suita-shi, Osaka, Japan, hereinafter “Luxna”) and..
November 10, 2025
From Discovery to Commercial Supply: Accelerating the Development of Therapeutic Oligonucleotide Drugs
Frankfurt a.M. / Munich, November 10th, 2025. BioSpring, a world-leading CDMO for therapeutic oligonucleotide manufacturing and analysis, and..
October 9, 2025
BioSpring Enters Strategic Partnership with Luxna Biotech to Offer Manufacture of Oligonucleotides with Luxna’s advanced XNA Amidites
Frankfurt am Main, Germany. BioSpring, a leading supplier of high-quality therapeutic oligonucleotides, today announced a new collaboration with..
